

PRODUCT INFORMATION



Tafluprost-d₄ Item No. 9002405

Formal Name: (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid-d₄, 1-methylethyl ester

Synonym: AFP-168-d₄

MF: C₂₅H₃₀D₄F₂O₅

FW: 456.6

Chemical Purity: ≥98% (Tafluprost)


Deuterium

Incorporation: ≥99% deuterated forms (d₁-d₄); ≤1% d₀

Supplied as: A solution in methyl acetate

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tafluprost-d₄ is intended for use as an internal standard for the quantification of tafluprost (Item No. 10005440) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Tafluprost-d₄ is supplied as a solution in methyl acetate. To change the solvent, simply evaporate the methyl acetate under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of tafluprost-d₄ in these solvents is approximately 30 mg/ml.

Description

Tafluprost is a prodrug form of the FP receptor agonist tafluprost (free acid) (Item No. 10005439) and a derivative of the prostaglandin F_{2α} (PGF_{2α}; Item Nos. 16010 | 16020).¹ It decreases pupillary diameter in cats when applied topically at doses of 0.0001 or 0.001% v/v.¹ Ocular administration of tafluprost (0.0005% v/v) reduces intraocular pressure in normotensive monkeys.¹ Formulations containing tafluprost have been used in the treatment of open-angle glaucoma and ocular hypertension.

Reference

1. Nakajima, T., Matsugi, T., Goto, W., *et al.* New fluoroprostaglandin F_{2α} derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. *Biol. Pharm. Bull.* **26(12)**, 1691-1695 (2003).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/30/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM